Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.
Status:
Completed
Trial end date:
2018-09-26
Target enrollment:
Participant gender:
Summary
This was a Phase Ib/II study of the ALK inhibitor ceritinib in combination with the CDK4/6
inhibitor LEE011 in patients with ALK-positive non-small cell lung cancer.
The purpose of the study was to determine the MTD/RP2D of the LEE011 and ceritinib
combination and evaluate whether the combination was safe and had beneficial effects in
ALK-positive advanced non-small cell lung cancer patients.
This trial did not progress to Phase II. Trial population terminated before reaching Phase II